# The Efficacy and Safety of D745 Added to D150 Plus D759 Therapy in Patients with Type 2 Diabetes

> **NCT05566028** · PHASE3 · COMPLETED · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 172 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** D745 formulation I
- **DRUG:** D745 formulation II
- **DRUG:** D745 Placebo

## Key facts

- **NCT ID:** NCT05566028
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-12
- **Primary completion:** 2024-01-10
- **Final completion:** 2024-07-23
- **Target enrollment:** 172 (ACTUAL)
- **Last updated:** 2024-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05566028

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05566028, "The Efficacy and Safety of D745 Added to D150 Plus D759 Therapy in Patients with Type 2 Diabetes". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05566028. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*